Dupilumab, Lebrikizumab, Tralokinumab All Beat Placebo in Adolescent Eczema, No Clear WinnerNew Treatments Show Promise for Severe Adolescent Atopic Dermatitis

The Annals of pharmacotherapy Published October 1, 2026 Study authors: Li Kevin H, Duffy Emily K, Luong Jonathan, Devine Beth PubMed ↗ DOI ↗ Editorial oversight: Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway

Interpret biologic efficacy in adolescent AD cautiously; certainty is low and no agent is clearly superior.

This systematic review with network meta-analysis examined dupilumab, lebrikizumab, and tralokinumab versus placebo in adolescents aged 12 to 17 with moderate-to-severe atopic dermatitis. The analysis included 642 participants and assessed EASI-75 and IGA 0/1 at week 16.

For dupilumab 200/300 mg every 2 weeks versus placebo, the risk ratio was 5.2 for EASI-75 (95% CrI 2.6, 12.0) and 12.0 for IGA 0/1 (95% CrI 3.3, 78.0), both favoring dupilumab. The wide credible intervals for IGA 0/1 indicate substantial uncertainty around the magnitude of effect.

The authors reported no strong evidence of superiority of one treatment over another. Certainty of the evidence was low. Adverse events, serious adverse events, discontinuations, and tolerability were not reported. Funding and conflicts of interest were not reported.

These findings support the use of these biologics over placebo in this population but do not establish a preferred agent. The low certainty of evidence and absence of head-to-head superiority signals warrant cautious interpretation when selecting among dupilumab, lebrikizumab, and tralokinumab.

How this fits prior evidence

This network meta-analysis extends prior coverage of dupilumab in pediatric atopic dermatitis, which previously focused on severe disease and a possible temporal association with vitiligo. It provides comparative efficacy estimates across three biologics versus placebo in adolescents, a population not addressed in earlier coverage. The finding of no strong evidence of superiority among agents contrasts with the implicit assumption that one biologic may be preferred. It also complements early MSC therapy evidence, which remains limited to small trials, by offering pooled estimates from a larger adolescent dataset, though certainty remains low.

Researchers looked at how three different medications, including dupilumab, lebrikizumab, and tralokinumab, performed for adolescents aged 12 to 17. These patients had moderate to severe atopic dermatitis. The study compared these treatments against a placebo over a 16-week period.

The results showed that dupilumab was more effective than a placebo in helping patients reach specific improvement goals. Specifically, those taking dupilumab were more likely to see a 75% improvement in their skin condition and achieve a nearly clear skin score. However, the researchers noted that the overall certainty of this evidence was low.

Because the evidence is not yet firm, it is currently unclear if one of these treatments is better than the others. Patients and families should talk to a doctor to decide which treatment is best for their specific needs. This study highlights potential options but does not prove one specific drug is the best choice for everyone.

What this means for you:

Dupilumab showed better results than a placebo for teens with severe eczema, but evidence is currently limited.

Common questions

How effective is dupilumab for teenage eczema?

In a study of 642 adolescents, dupilumab showed a much higher likelihood of success compared to a placebo. Specifically, patients on dupilumab were more likely to achieve a 75% improvement in their skin scores and reach a nearly clear skin status after 16 weeks.

Are these treatments safe for teenagers?

The study did not report specific data on side effects, serious adverse events, or how well the treatments were tolerated by the participants. You should speak with a healthcare provider to discuss the safety and risks of these specific medications.

Is one of these medications better than the others?

The current evidence is not strong enough to say if one treatment is better than the others. While dupilumab showed results better than a placebo, there is no clear evidence yet to prove it is superior to lebrikizumab or tralokinumab.

Study Details

Study typeSystematic review

EvidenceLevel 1

Follow-up0.5 mo

PublishedOct 2026

PMID41635230

View Original Abstract ↓

BACKGROUND: Novel interventions, particularly biologic therapies, have been shown to be efficacious and safe in treating atopic dermatitis (AD) in adolescents. However, the comparative efficacy and safety of biologic interventions in adolescents with moderate-to-severe AD have not been explored. OBJECTIVE: To compare efficacy and safety measures in clinical trials of biologic interventions in adolescents aged 12 to 17 with moderate-to-severe AD. METHODS: MEDLINE, Embase, and trial registries were searched for double-blind, randomized placebo-controlled clinical trials assessing the efficacy of biologic therapies in adolescents with moderate-to-severe AD. Arm-level Bayesian network meta-analyses (NMAs) were performed and certainty of evidence was assessed through the Confidence in Network Meta-Analysis grading tool. Primary outcomes included the proportion of participants who achieved 75% improvement in Eczema Area and Severity Index score (EASI-75) and the proportion of participants who achieved 0 (clear) or 1 (almost clear) value on the Investigators' Global Assessment (IGA 0/1) at week 16. RESULTS: Four trials evaluating 3 drugs, dupilumab, lebrikizumab, and tralokinumab, representing 642 study participants were analyzed. Two dosing options were assessed for dupilumab and tralokinumab. Compared with placebo, the greatest effect was observed with dupilumab 200/300 mg every 2 weeks in both EASI-75 (risk ratio [RR]: 5.2; 95% credible interval [CrI]: 2.6, 12.0) and IGA 0/1 (RR: 12.0; 95% CrI: 3.3, 78.0). No differences were found between treatments. Certainty of the evidence was low. CONCLUSION AND RELEVANCE: Although there is some evidence that dupilumab may be more efficacious than lebrikizumab or tralokinumab, our findings suggest that there is no strong evidence of superiority of one treatment over another.

Dupilumab, Lebrikizumab, Tralokinumab All Beat Placebo in Adolescent Eczema, No Clear WinnerNew Treatments Show Promise for Severe Adolescent Atopic Dermatitis

How this fits prior evidence

Common questions

Study Details

Adalimumab significantly improves ACR70 and PASI100 outcomes in patients with psoriatic arthritis

Trial data shows adalimumab helps manage psoriatic arthritis symptoms

Clinical research that matters. Delivered to your inbox.

Dupilumab, Lebrikizumab, Tralokinumab All Beat Placebo in Adolescent Eczema, No Clear WinnerNew Treatments Show Promise for Severe Adolescent Atopic Dermatitis

How this fits prior evidence

Common questions

More on Atopic Dermatitis

Study Details

Adalimumab significantly improves ACR70 and PASI100 outcomes in patients with psoriatic arthritis

Trial data shows adalimumab helps manage psoriatic arthritis symptoms

Clinical research that matters. Delivered to your inbox.

Related in Dermatology

From Other Specialties